Incyte Corp at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 03:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we're delighted that you're all here in person for the health care conference this year. We're kicking off this morning with Incyte, and I'm joined by the company's CEO, Herve Hoppenot. So I'll pass it over to him.

Herve Hoppenot - Incyte Corporation - Chairman, President & CEO

Thank you, Jess, and welcome to everybody in person here. So what I will do, I think the format for this year will be a 20-minute presentation, and then we can have a Q&A for the following time.

So let's move to the next slide. And obviously, I will be making forward-looking statements in my presentation. So I refer to the SEC document we have on our website. So to start, what I would like to do is a reminder of who is Incyte and where we are today. As you can see on the slide, I mean, it's really a fully integrated company from discovery to commercial.

We have 3 different platforms we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot